Our observations preliminarily demonstrate that HER2 assessment on CTCs perhaps overcomes spatio-temporal heterogeneity of HER2 status by tumor biopsies and more precisely tailors anti-HER2 treatment. Here, ERBB2 is linked to neoplasm.